

# Ruth Exner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2954127/publications.pdf>

Version: 2024-02-01

25  
papers

944  
citations

840585

11  
h-index

642610

23  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1466  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant denosumab in breast cancer (ABCSCG-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2015, 386, 433-443.	6.3	444
2	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSCG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 339-351.	5.1	167
3	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	7.7	77
4	Prognostic value of <sc>HMGB</sc> 1 in early breast cancer patients under neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 2350-2358.	1.3	34
5	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	3.2	29
6	Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSCG-53, GBC 101). <i>Breast</i> , 2021, 60, 98-110.	0.9	28
7	Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers. <i>British Journal of Cancer</i> , 2015, 113, 1035-1045.	2.9	25
8	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSCG 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	1.3	24
9	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSCG-18 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 500-500.	0.8	23
10	Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 421-427.	1.1	21
11	Adjuvant Bisphosphonates and Breast Cancer Survival. <i>Annual Review of Medicine</i> , 2016, 67, 1-10.	5.0	20
12	Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 18.	1.3	12
13	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 679-692.	1.4	10
14	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	1.4	9
15	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 505-511.	1.1	4
16	Trocar-site evisceration of the vermiform appendix following laparoscopic sigmoid colectomy: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 31, 273-275.	0.2	4
17	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSCG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	2.9	3
18	The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11601-e11601.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Local therapies for breast cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 181-184.	0.3	2
20	Post San Antonio Breast Cancer Symposium 2018. Memo - Magazine of European Medical Oncology, 2019, 12, 257-260.	0.3	2
21	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	0.6	1
22	Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.. Journal of Clinical Oncology, 2018, 36, 589-589.	0.8	1
23	Differential effects of epirubicin and docetaxel on the immune system in patients with breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 588-588.	0.8	1
24	Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer.. Journal of Clinical Oncology, 2019, 37, e12114-e12114.	0.8	0
25	Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression. Cancer Research, 2022, 82, P1-02-06-P1-02-06.	0.4	0